Testing tarlatamab for recurrent gynecological neuroendocrine carcinoma
This study tests an investigational drug called tarlatamab in people with a rare type of cancer called neuroendocrine carcinoma that started in the female reproductive tract (cervix, vulva, or vagina). The goal is to see if tarlatamab can shrink or control the cancer. To participate, your cancer must have progressed after at least one line of platinum-based chemotherapy. You must also have measurable disease and be willing to provide a tumor sample.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of neuroendocrine carcinoma of the cervix, vulva, or vagina.
- You must have received at least one prior line of platinum-based chemotherapy for advanced disease.
- Your cancer must have grown or spread despite your most recent treatment.
- You must have adequate organ function (bone marrow, liver, and kidneys) as per standard lab tests.
- You must be willing to provide a tumor tissue sample (or allow a new biopsy) for research testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
This trial tests a new drug called tarlatamab for people with advanced small cell or neuroendocrine cancers that started outside the lung (like in the stomach, bladder, or head and neck) and have grown after initial chemotherapy. It aims to see if this treatment can shrink or control the cancer.
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
Hear when a new Diagnosis of Neuro-endocrine Carcinoma of the Gynecological Tract trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.